Volume : 11, Issue : 02, February – 2024
Title:
UNLOCKING HOPE: THE PROMISE OF IVACAFTOR, LUMACAFTOR, THEIR COMBINATION IN CYSTIC FIBROSIS TREATMENT AND GENE THERAPY
Authors :
Poojitha Modepalli, Ramesh Chinnabala, Om Vinay Dappu, Ramarao Tadikonda, Gayatri Devi Yasa*
Abstract :
Cystic fibrosis (CF) is an inherited disorder that causes severe damage to the lungs, digestive system and other organs in the body. A protein that controls the flow of salt into and out of cells are altered in cystic fibrosis due to a flaw (mutation) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. As a result, sweat becomes more salted and the respiratory, digestive, and reproductive systems produce thick, sticky mucus. A novel medicinal drug called ivacaftor modifies the function of the CFTR channel. For patients who are homozygous for the F508del mutation in the CFTR gene, lumacaftor is a protein chaperone that is used in conjunction with ivacaftor to treat cystic fibrosis. Lumacaftor-ivacaftor is indicated for treatment of CF in patients homozygous for the Phe-508del CFTR gene mutations. Without the treatment and perfect knowledge on the disease leads to death of the patient on suffering with CF. A significant step in the development of CF gene therapy was the cloning of the CFTR gene. This review mainly describes about the cystic fibrosis and its treatment ways and procedures. The drugs like ivacaftor, lumacaftor, different combinations of drugs and also discussed about the gene therapy and agents of gene therapy for cystic fibrosis.
Key words: Cystic fibrosis, ivacaftor, lumacaftor, gene therapy.
Cite This Article:
Please cite this article in press Gayatri Devi Yasa et al., Unlocking Hope: The Promise Of Ivacaftor, Lumacaftor, Their Combination In Cystic Fibrosis Treatment And Gene Therapy, Indo Am. J. P. Sci, 2024; 11 (02).
Number of Downloads : 10
References:
1. Condren ME, Bradshaw MD. Brief Review Article Ivacaftor: A Novel Gene-Based Therapeutic Approach for Cystic Fibrosis. J Pediatr Pharmacol Ther. 2013; 18(1):8-13.
2. Chen Q, Shen Y, Zheng J. A review of cystic fibrosis: Basic and clinical aspects. Animal Models and Experimental Medicine. John Wiley and Sons Inc; 2021; 4: p. 220–32.
3. Pittman JE, Ferkol TW. The evolution of cystic fibrosis care. Chest. 2015; 148(2):533–542.
4. Blasi F, Elborn JS, Palange P. Adults with cystic fibrosis and pulmonologists: New training needed to recruit future specialists, European Respiratory Journal. European Respiratory Society. 2019; 53(1):1-3.
5. Goubau C, Wilschanski M, Skalická V, Lebecque P, Southern KW, Sermet I, et al. Phenotypic characterisation of patients with intermediate sweat chloride values: Towards validation of the European diagnostic algorithm for cystic fibrosis. Thorax. 2009; 64(8):683–691.
6. Rafeeq MM, Murad HAS. Cystic fibrosis: Current therapeutic targets and future approaches. Journal of Translational Medicine. BioMed Central Ltd. 2017; 15(84):1-9.
7. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis, American Journal of Respiratory and Critical Care Medicine. 2003; 168:918–51.
8. Cooney AL, McCray PB, Sinn PL. Cystic fibrosis gene therapy: Looking back, looking forward, Genes. MDPI AG. 2018; 9:1-23.
9. Griesenbach U, Pytel KM, Alton EWFW. Cystic Fibrosis Gene Therapy in the UK and Elsewhere. Hum Gene Ther. 2015; 26(5):266–275.
10. Burney TJ, Davies JC. Gene therapy for the treatment of cystic fibrosis. Application of Clinical Genetics. Dove Medical Press Ltd. 2012, Vol 5, p. 29–36.
11. Lee JA, Cho A, Huang EN, Xu Y, Quach H, Hu J, et al. Gene therapy for cystic fibrosis: new tools for precision medicine, Journal of Translational Medicine. BioMed Central Ltd; 2021, Vol 19, 1-15.
12. Milla CE, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenfeld M. Lumacaftor/Ivacaftor in patients aged 6-11 years with cystic fibrosis and homozygous for F508del-CFTR. Am J Respir Crit Care Med. 2017; 195(7):912–920.